|Bid||49.22 x 800|
|Ask||74.05 x 800|
|Day's range||49.27 - 49.74|
|52-week range||40.38 - 56.18|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||24.76|
|Earnings date||06 Feb 2023 - 10 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||53.00|
QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
HILDEN, Germany & GERMANTOWN, Maryland, November 21, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the monkeypox (MPXV) test for its NeuMoDx automated PCR platform to strengthen surveillance and research into the current outbreak in non-endemic regions that has infected tens of thousands of people all over the world since first being identified in May 2022.